Sodium-glucose cotransporter 2 (SGLT2) inhibitor and application thereof

A co-transporter and inhibitor technology, applied in the field of medicine, can solve problems such as affecting the effect of diabetes treatment, and achieve the effects of inhibiting glucose reabsorption, lowering blood sugar levels, and improving insulin resistance.

Inactive Publication Date: 2019-03-12
CHONGQING UNIV OF TECH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the prediction of the International Diabetes Association, by 2025, the number of diabetes worldwide will increase to 300 million, of which more than 90% are type 2 diabetes, and the adverse reactions of traditional hypoglycemic drugs, drug interactions and diabetic complications all affect the The effect of diabetes treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitor and application thereof
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitor and application thereof
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 3

[0017] Example 1 Interaction between trelobatin and SGLT2 protein

[0018] Use the molecular docking simulation software Autodock and SGLT2 protein structure data to set the docking conditions with trilobatin, including: assuming that trilobatin interacts with SGLT2, on the one hand, the highly hydrophilic glycosyl part and the amino acid residues facing outward from the pocket On the other hand, trilobatin needs to have π-π interaction with the deeper hydrophobic part of the pocket. Special attention should be paid to the fact that the ASn75 and Tyr290 sites of SGLT2 are the key sites for its activity. Therefore, the key to determine whether trilobatin is an SGLT2 inhibitor is to see whether there is an interaction between trilobatin and these two sites.

[0019] The results of molecular docking confirmed that trilobatin interacts with SGLT2, and has hydrogen bonds with both Glu88 and Tyr263 sites of SGLT2. The specific docking results are as follows figure 1 shown.

Embodiment 2 3

[0020] Embodiment 2 The influence of trilobatin on glucose reabsorption in experimental animals

[0021] The specific experimental steps are as follows:

[0022] (1) Select 6 10-week-old C57BL6 mice and divide them into two groups with 3 mice in each group;

[0023] (2) One group was administered with 2g / kg of glucose, and the other group was simultaneously administered with 2g / kg of glucose and 10mg / kg of trilobatin;

[0024] (2) Take blood from the tail vein at 0, 15, 30, 60 and 120 minutes respectively, and measure the blood sugar content with a Johnson & Johnson blood glucose meter.

[0025] Experimental results such as figure 2 shown, see figure 2 , Compared with the control group, the blood glucose levels of the experimental animals given trilobatin were significantly lower, indicating that trilobatin inhibits the absorption of glucose.

Embodiment 3 3

[0026] Example 3 Effect of trilobatin on blood sugar and glucose tolerance in insulin-resistant diabetic mice

[0027] The specific experimental steps are as follows:

[0028] (1) Select 12 10-12-week-old ob / ob mice and divide them into two groups. One group is the control group, and the other group is given 10 mg / kg trilobatin by intragastric administration every day for 4 consecutive weeks. C57BL6 mice of the same age were used as controls.

[0029] (2) After 4 weeks, the mice were starved for 12 hours, and the fasting blood glucose levels of the mice in each group were measured respectively;

[0030] (3) Simultaneously, by intragastric administration of glucose at 2 g / kg, blood was taken from the tail vein at 0, 15, 30, 60 and 120 minutes respectively, and the content of blood sugar was measured with a Johnson & Johnson blood glucose meter, and after intragastric administration of trilobatin, each Changes in glucose tolerance of group animals, to clarify whether trelobati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The SGLT2 inhibitor is trilobatin, and the specific structure of the trilobatin is shown as the following formula (please seethe specifications for the formula); and the trilobatin and the SGLT2 interact with each other, the trilobatin is in hydrogen bond connection with ASn75 and Tyr290 sites of the SGLT2, and thus the trilobatin can significantly inhibit glucose reabsorption, lowers the overall blood glucose level of an experimental subject, and meanwhile, can further improve insulin resistance of the experimental subject effectively.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a sodium-glucose co-transporter 2 inhibitor and application thereof. Background technique [0002] Diabetes is a common metabolic disease. According to the prediction of the International Diabetes Association, by 2025, the number of diabetes worldwide will increase to 300 million, of which more than 90% are type 2 diabetes, and the adverse reactions of traditional hypoglycemic drugs, drug interactions and diabetic complications all affect the Effects of diabetes treatment. [0003] In recent years, new hypoglycemic drugs of sodium-glucose cotransporter (sodium-glucose cotransporter) inhibitors have received widespread attention. Modern studies have found that organs related to blood sugar regulation, except the pancreas (islet β cells), liver, and In addition to skeletal muscle, it also includes intestinal tract, brain, adipose tissue and kidney, and the kidney plays a key regulatory ro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07H15/203A61P3/10A61P9/10A61P5/50
CPCA61P3/10A61P5/50A61P9/10C07H15/203
Inventor 殷菲刘建辉刘敏王路静李心淦吴玉翠
Owner CHONGQING UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap